Galinpepimut-S, a WT1-Targeting Immuno-Oncology Treatment, Induces Specific, Robust and Durable Immune Responses (IRs) in Patients (Pts) with High-Risk (HR) Multiple Myeloma (MM)

Guenther Koehne, Sean Devlin, Neha Korde, Sham Mailankody, Landau Heather, Hani Hassoun, Alexander Lesokhin, Nikoletta Lendvai, David Chung, Nicholas Sarlis, Sergio Giralt, Ola Landgren

Research output: Contribution to conferencePresentation

Original languageAmerican English
DOIs
StatePublished - Jan 9 2017
EventClinical Lymphoma, Myeloma & Leukemia -
Duration: Jan 9 2017 → …

Conference

ConferenceClinical Lymphoma, Myeloma & Leukemia
Period1/9/17 → …

Disciplines

  • Medicine and Health Sciences
  • Immunology and Infectious Disease

Cite this